Equities researchers at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN – Get Free Report) in a note issued to investors on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Separately, Lake Street Capital dropped their price target on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, August 23rd.
Get Our Latest Stock Analysis on Evogene
Evogene Stock Performance
Evogene (NASDAQ:EVGN – Get Free Report) last posted its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.94). The business had revenue of $0.91 million for the quarter. Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Evogene stock. BNP Paribas Financial Markets increased its position in Evogene Ltd. (NASDAQ:EVGN – Free Report) by 30.8% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 91,400 shares of the biotechnology company’s stock after purchasing an additional 21,500 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.22% of Evogene worth $69,000 as of its most recent filing with the Securities & Exchange Commission. 10.40% of the stock is owned by hedge funds and other institutional investors.
Evogene Company Profile
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Recommended Stories
- Five stocks we like better than Evogene
- How to Calculate Inflation Rate
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- The How and Why of Investing in Gold Stocks
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.